1. Executive Summary & Investment Thesis

This report initiates coverage of Zoetis Inc. (NYSE: ZTS) with a BUY rating and a 12-month price target of $188, representing a significant potential upside from current levels.

Zoetis stands as the undisputed global leader in the animal health industry, a sector underpinned by powerful and durable secular growth trends.

The company has a distinguished history of outperforming the broader market, driven by a best-in-class portfolio, a wide economic moat, and exceptional financial discipline.

However, the stock has recently experienced significant underperformance, trading near its 52-week low despite its strong fundamentals and a chorus of bullish analyst ratings.

This report posits that this divergence represents a compelling investment opportunity born from a “Great Disconnect”: the market’s intense focus on manageable, near-term headwinds has overshadowed the company’s robust, long-term intrinsic value.

The investment thesis is centered on the argument that Zoetis is a premier, wide-moat business currently available at a rare discount. The primary factors weighing on the stock—namely, a slower-than-anticipated U.S. launch of its new osteoarthritis (OA) pain franchise and a pending antitrust investigation in the European Union—are temporary and have been disproportionately priced in by the market.

Meanwhile, the fundamental drivers of the business remain firmly intact: the non-discretionary nature of pet healthcare spending, the rising global demand for animal protein, and Zoetis’s unparalleled innovation engine that consistently delivers market-leading products.

While the stock commands a premium price-to-earnings (P/E) multiple relative to many peers, this is justified by its superior profitability and growth.

More importantly, a rigorous Discounted Cash Flow (DCF) analysis reveals a significant undervaluation, with multiple models suggesting a fair value well above the current share price.

The current market price offers a compelling entry point for long-term, growth-oriented investors to acquire a best-in-class industry leader before the market’s focus shifts back from short-term uncertainty to long-term value creation.

2. Business & Market Landscape

2.1. Company Profile: The Undisputed Leader in Animal Health

Zoetis Inc. is the world’s largest company focused solely on animal health. Spun out of Pfizer’s animal health division in a 2013 Initial Public Offering (IPO), Zoetis has established itself as the dominant force in the industry, driven by a singular purpose: “to nurture our world and humankind by advancing care for animals”.

The company operates on a global scale, with its products making a difference in over 100 countries and serving a diverse customer base that includes veterinarians, livestock producers, and pet owners.

The business is strategically structured into two principal segments, which creates a balanced and resilient revenue model capable of navigating different economic cycles:

• Companion Animals: This segment, which includes products for dogs, cats, and horses, is the company’s primary growth engine and now accounts for approximately 68% of total revenue. It benefits from the powerful trend of pet humanization and the resulting increase in healthcare spending.
• Livestock: This segment provides a portfolio of products for cattle, swine, poultry, fish, and other farm animals, representing about 32% of revenue. It offers stability and cash flow, driven by the fundamental global need for a safe and sustainable food supply.

Since its IPO, Zoetis has consistently executed a strategy centered on “innovation and commercial excellence,” allowing it to grow at an average annual rate of 8%, significantly outpacing the broader animal health market’s 5% compound annual growth rate (CAGR).

2.2. Product Portfolio Analysis: A Diversified Engine of Growth

Zoetis’s market leadership is built upon a broad and innovative portfolio of medicines, vaccines, diagnostics, and technologies. The portfolio is well-diversified across therapeutic areas, ensuring that the company is not overly reliant on any single product.

2.2.1. Companion Animal Segment

This segment has been the cornerstone of Zoetis’s growth story, fueled by a series of blockbuster product launches. Its key franchises include:

• Parasiticides (24% of revenue): This category is led by the highly successful Simparica Trio, a “triple combination” oral treatment that protects dogs from fleas, ticks, heartworm disease, and intestinal parasites. The Simparica franchise has been a formidable growth driver, expanding 17% operationally in the second quarter of 2025.
• Dermatology (18% of revenue): Zoetis effectively created and has since dominated the market for canine atopic dermatitis with its innovative products Apoquel and Cytopoint. Even more than a decade after launch, this franchise continues to deliver remarkable double-digit growth, increasing 11% operationally in Q2 2025, a testament to the durability of true innovation and the chronic nature of the condition it treats.
• Pain and Sedation (9% of revenue): This is the company’s newest frontier, featuring a revolutionary class of treatments for osteoarthritis (OA) pain. The launch of Librela (for dogs) and Solensia (for cats) marked the introduction of monoclonal antibody (mAb) therapy to the animal health space, targeting a massive and underserved market. While these products have seen strong initial uptake internationally, their recent performance in the U.S. has been a primary source of investor concern and recent stock volatility.

2.2.2. Livestock Segment

While growing more slowly than the companion animal business, the livestock segment provides essential diversification and stable cash flow. Key product lines include vaccines, anti-infectives like the market-leading Draxxin, and other solutions for cattle, swine, and poultry health.

Recent performance has been impacted by the strategic divestiture of its medicated feed additive (MFA) portfolio, but on an organic basis, the segment continues to show modest growth, driven by global food production needs.

The very nature of Zoetis’s strategy—to invent entirely new markets with groundbreaking products—is both its greatest strength and a source of its current vulnerability.

When the company launched Apoquel, it didn’t just introduce a new drug; it created the billion-dollar market for canine allergic dermatitis treatment from scratch. This established Zoetis as the undisputed standard of care, granting it years of monopoly-like pricing power and margins. This monumental success, however, set an incredibly high bar for all future innovations. The market, in turn, priced Zoetis’s stock with the built-in assumption that it could replicate this feat with its next major launch, the OA pain franchise of Librela and Solensia.

Consequently, when the Q2 2025 earnings call revealed a 7% operational decline in the OA pain franchise and management acknowledged a slower-than-expected U.S. adoption curve, the market’s reaction was severe. The resulting stock sell-off was not merely a recalibration of revenue forecasts for a single product line. It represented a crisis of confidence in the company’s entire innovation-led growth narrative.

The volatility, therefore, is not just about Librela’s sales figures; it is about the market questioning whether Zoetis’s “innovation engine” can continue to fire on all cylinders and justify the stock’s premium valuation. Any analysis of the company’s future must therefore treat the performance of this new franchise as a key barometer for the viability of the company’s long-term growth algorithm.

2.3. The Animal Health Industry: Secular Tailwinds and Competitive Dynamics

Zoetis operates within an attractive industry characterized by defensive qualities and supported by powerful, long-term secular tailwinds. These trends provide a durable foundation for sustained growth, largely insulated from the volatility of broader economic cycles.

• The Humanization of Pets: This is the single most important driver for the companion animal market. A growing number of households own pets, and owners increasingly view them as integral family members. This emotional bond translates directly into a higher willingness to spend on premium healthcare, including preventative medicines, advanced treatments for chronic conditions, and wellness products. This trend has proven remarkably resilient, even in the face of high inflation—a phenomenon now known as “petflation.” Despite rising costs for veterinary services and pet products, overall spending continues to climb, as many owners consider pet healthcare a non-discretionary expense.
• Rising Global Protein Demand: The livestock market is driven by fundamental global demographics. A growing world population, combined with a rising global middle class, is increasing the demand for animal-based protein like meat, milk, and eggs. This necessitates healthier and more productive livestock, driving demand for the vaccines, medicines, and diagnostics that Zoetis provides to ensure a safe, efficient, and sustainable food supply.

The competitive landscape is concentrated among a few large players. Zoetis’s primary competitors include the animal health divisions of large pharmaceutical companies like Merck & Co. (Merck Animal Health) and standalone companies such as Elanco Animal Health and IDEXX Laboratories, which specializes in diagnostics. While Zoetis holds the largest market share, competition is dynamic and intensifying.

The company has noted the expected arrival of new competitors in its lucrative dermatology franchise in late 2024, which could introduce pricing pressure over time.

3. Financial Health & Performance Analysis

A deep dive into Zoetis’s financial statements reveals a company with a stellar track record of execution, characterized by consistent growth, best-in-class profitability, and robust cash flow generation.

3.1. Revenue & Margin Trends: A Picture of Consistent Execution

Zoetis has demonstrated a remarkable ability to consistently grow its top line. Annual revenue has climbed steadily, from $8.08 billion in 2022 to $8.54 billion in 2023, and reaching $9.26 billion in 2024. This represents a reported growth rate of 8% in the most recent full fiscal year, well ahead of the industry average.

The company’s most recent quarterly report for Q2 2025 continued this trend of underlying strength. While reported revenue grew a modest 4.2% year-over-year to $2.46 billion, this figure was negatively impacted by the divestiture of the MFA portfolio. A more accurate measure of the core business’s health is the organic operational growth rate, which strips out the effects of acquisitions, divestitures, and currency fluctuations. On this basis, Zoetis delivered an impressive 8% growth, demonstrating that underlying demand for its key products remains robust.

Even more impressive than its revenue growth are the company’s profitability margins, which are among the best in the healthcare sector. In Q2 2025, the company reported an adjusted gross margin of 73.7%, a clear indicator of its significant pricing power and the high value placed on its innovative products. This efficiency carries through the income statement, with a reported operating margin of approximately 37.5% and a net profit margin of nearly 28%, showcasing exceptional operational control and profitability.

3.2. Profitability & Returns: Best-in-Class Efficiency

Zoetis stands out for its extraordinary ability to generate high returns on capital, a key indicator of a high-quality business and effective management. The company’s Return on Equity (ROE) is exceptionally high, standing at over 56%.

This figure signifies that for every dollar of shareholder equity invested in the business, management is generating more than 56 cents in annual net profit—a level of efficiency that few companies of any industry can match.

Similarly, its Return on Invested Capital (ROIC), which measures the return generated from all capital employed (both debt and equity), is a top-tier 24.7%.

This demonstrates that the company’s core business operations are immensely profitable and that it has a wide economic moat protecting it from competition. These elite return metrics are a primary reason why the stock has historically commanded, and continues to deserve, a premium valuation compared to its peers.

3.3. Cash Flow & Balance Sheet Strength

Zoetis is a formidable cash-generating machine. Net cash provided by operating activities has shown a strong upward trend, growing from $1.91 billion in 2022 to $2.35 billion in 2023, and surging to $2.95 billion in 2024. This robust and predictable cash flow provides the company with significant financial flexibility.

Management has pursued a shareholder-friendly capital allocation policy, consistently returning this cash to investors through two primary channels:

1. Dividends: Zoetis has a strong track record of dividend growth.
2. Share Repurchases: The company is actively buying back its own stock, with a $6 billion share repurchase authorization currently in place. In the first half of 2025 alone, Zoetis returned $781 million to shareholders via buybacks.

The company’s balance sheet is healthy and well-managed. As of the end of Q2 2025, total debt stood at approximately $6.65 billion. While this is a substantial figure, it is easily serviceable given the company’s immense profitability. Its interest coverage ratio is over 15x, meaning its operating income is more than 15 times its interest expense, indicating a very low risk of financial distress.

Table 1: Zoetis Inc. Key Financial & Operational Metrics

Financial Highlight ($ Millions)	2022	2023	2024
Revenue	$8,080	$8,544	$9,256
Revenue Growth (Reported)	4%	6%	8%
Gross Profit	$5,607	$5,989	$6,618
Gross Margin	69.4%	70.1%	71.5%
Operating Income	$2,780	$3,101	$3,450
Operating Margin	34.4%	36.3%	37.3%
Net Income	$2,114	$2,344	$2,486
Diluted EPS	$4.49	$5.07	$5.47
Net Cash from Operations	$1,912	$2,353	$2,953
Free Cash Flow	$1,327	$1,625	$2,299

Source: Derived from 2024 Annual Report and other financial data. Note: Gross Profit and Operating Income are calculated for illustrative purposes based on reported margins and revenue where not explicitly stated in a single source.

4. External Factors & Key Investment Risks

While Zoetis possesses a formidable business model, it is not immune to external pressures. Investors must consider several key risks, including macroeconomic headwinds, a significant regulatory challenge, and an evolving competitive landscape.

4.1. Macroeconomic Headwinds: The “Petflation” Paradox

The current macroeconomic environment presents a complex picture for the animal health industry. On one hand, the trend of pet humanization has made spending on pet care remarkably resilient. This phenomenon, dubbed “petflation,” has seen prices for pet products and veterinary services rise faster than the general Consumer Price Index (CPI), yet owners have largely continued to increase their spending, treating these costs as non-discretionary. This provides a strong, defensive underpinning for Zoetis’s business.

However, there are emerging signs that sustained inflation and economic uncertainty are beginning to strain household budgets. Recent surveys indicate that a growing number of pet owners are now actively seeking ways to cut costs.

This includes trading down to cheaper brands of pet food, reducing the frequency of routine veterinary visits, and in some cases, delaying or forgoing recommended procedures. This creates a potential headwind for Zoetis. While demand for its essential medicines for chronic conditions like Apoquel is likely to remain stable, the adoption of newer, premium-priced preventative treatments like Librela could face resistance as consumers become more price-sensitive. This directly connects the broader economic climate to the specific challenges observed in the company’s recent product launch.

Furthermore, on the livestock side of the business, persistently high interest rates increase the cost of capital for farmers and producers. This can squeeze their profit margins and potentially lead to reduced spending on animal health products as they look to control input costs.

4.2. Geopolitical & Regulatory Environment: The EU Antitrust Overhang

The single most significant and immediate risk facing Zoetis is a formal antitrust investigation launched by the European Commission in March 2024.

The investigation centers on allegations that Zoetis may have abused its dominant market position to protect its key OA pain drug, Librela.

Specifically, regulators are examining whether Zoetis acquired a late-stage competing pipeline product and subsequently terminated its development to prevent it from reaching the market and challenging Librela’s leadership.

This probe represents a major overhang for the stock for two reasons. First, the potential financial penalty is substantial. If found to have breached EU antitrust rules, Zoetis could be fined up to 10% of its global turnover, a penalty that could approach $1 billion. Second, and perhaps more importantly, the investigation creates a cloud of uncertainty that is likely depressing the stock’s valuation multiple. The market dislikes uncertainty, and the unknown outcome and timing of this regulatory action are weighing on investor sentiment.

This situation, however, also presents a potential upside catalyst. The current stock price is factoring in a negative outcome. Should the investigation be resolved with a smaller-than-expected fine, or in a best-case scenario, be dropped entirely, the removal of this uncertainty would act as a powerful “coiled spring” for the stock. The share price could re-rate significantly higher as the legal and financial risk evaporates, unlocking value for investors who were willing to hold the stock through this period of ambiguity.

Beyond this specific probe, Zoetis has managed other geopolitical risks adeptly. For instance, following the conflict in Ukraine, the company suspended all new investments and promotional activities in Russia but continues to supply essential medicines and vaccines, limiting its exposure while adhering to its core mission.

4.3. Competitive & Supply Chain Pressures

Zoetis operates in a competitive industry and must constantly innovate to maintain its leadership. The company faces two key pressures in this domain:

• Intensifying Competition: The immense success of Zoetis’s products, particularly in the companion animal space, naturally attracts competition. Management has already guided the market to expect new competitive pressures in the dermatology franchise beginning in the fourth quarter of 2024. The arrival of new entrants or generic alternatives could, over time, erode market share and put pressure on the premium pricing Zoetis currently enjoys.
• Supply Chain Risk: As a global pharmaceutical manufacturer, Zoetis is exposed to the inherent risks of a complex international supply chain. This includes reliance on active pharmaceutical ingredients (APIs) sourced from countries like China and India, vulnerability to geopolitical trade tensions and tariffs, and fluctuations in freight and logistics costs. While the company has not reported any major supply disruptions, this remains a systemic background risk for the entire industry.

5. Share Price Volatility & Market Sentiment

5.1. Diagnosing Recent Underperformance

Despite reporting strong underlying financial results, Zoetis’s stock has been a significant laggard. Over the past year, the share price has declined by more than 22% and is currently trading near its 52-week low, a stark contrast to the performance of the broader S&P 500 index. This sharp downturn can be attributed to a confluence of factors that have collectively soured investor sentiment.

The primary drivers of this recent volatility include:

1. Librela Growth Concerns: The most acute catalyst for the sell-off was the Q2 2025 earnings report, which revealed a surprising 7% operational decline in the company’s new OA pain franchise. This result alarmed investors who had modeled Librela and Solensia as the company’s next billion-dollar growth engines. Management’s acknowledgment of “adoption headwinds” in the crucial U.S. market confirmed that the launch was not proceeding as smoothly as hoped, creating uncertainty around future growth projections.
2. EU Antitrust Investigation: The announcement of the formal investigation in Europe created a significant legal and financial overhang. The uncertainty surrounding the potential outcome and financial penalty continues to weigh on the stock, causing investors to demand a higher risk premium.
3. Macroeconomic Worries: Broad concerns about a potential economic slowdown and its impact on consumer discretionary spending have cast a pall over the entire pet care sector. As discussed, fears that pet owners may cut back on veterinary care are pressuring stocks like Zoetis.
4. Valuation Compression: In an environment of higher interest rates, growth stocks with high valuation multiples are naturally susceptible to compression. As discount rates rise, the present value of future earnings decreases, leading to lower stock prices, even if the underlying business fundamentals remain unchanged.

5.2. Gauging Investor Sentiment: Wall Street vs. Main Street

There is a notable divergence in sentiment between professional Wall Street analysts and retail investors discussing the stock on public forums.

Wall Street (Analysts): The professional analyst community remains overwhelmingly bullish on Zoetis. A consensus of 15-25 analysts covering the stock shows a strong “Buy” or “Moderate Buy” rating. The average 12-month price target from these analysts falls in a range of approximately $188 to $207, which implies a potential upside of 30% to 40% from the stock’s current price. This indicates that Wall Street largely views the recent issues as temporary and believes the stock is significantly undervalued relative to its long-term prospects.

Table 2: Summary of Recent Wall Street Analyst Ratings & Price Targets

Brokerage Firm	Date	Rating	Price Target ($)
UBS	Oct 19, 2025	Hold	$158
Argus Research	Sep 09, 2025	Buy	$190
Piper Sandler	Aug 10, 2025	Buy	$215
Morgan Stanley	Jul 28, 2025	Buy	$221
Stifel	Jun 18, 2025	Hold (Downgrade)	$160

Source: Compiled from various analyst rating reports.

Main Street (Reddit): Sentiment among retail investors, as gleaned from discussions on forums like r/ValueInvesting and r/dividends, is more nuanced.

There is universal praise for the quality of Zoetis’s business, its dominant market position, and the strength of its products, with some posters who work in the veterinary field confirming the company’s ubiquitous presence in clinics. However, this admiration is frequently tempered by a persistent concern: the stock’s valuation. Words like “pricey,” “expensive,” and “overvalued” are common, with many investors citing the high P/Eatio as a barrier to entry.

A recurring theme is that while they love the company, they are waiting for a significant market correction or a “stock market crash” to initiate a position at a more attractive price. This highlights a clear disconnect between their appreciation for the underlying business and their willingness to pay the current market multiple.

6. Valuation Analysis & Price Target Calculation

A comprehensive valuation of Zoetis reveals a tale of two perspectives. While traditional relative valuation metrics suggest the stock is expensive, a more fundamental analysis based on its future cash flows indicates it is significantly undervalued.

6.1. Comparable Company Analysis: A Premium Price for a Premium Business

When compared to a basket of its peers in the pharmaceutical and animal health sectors, Zoetis consistently trades at a premium valuation. Its forward P/E ratio of approximately 25x is substantially higher than that of large-cap pharma companies like Merck & Co. (P/E ~11-14x) and Sanofi (P/E ~12x). Its direct competitor in animal health diagnostics, IDEXX Laboratories, trades at an even richer multiple of over 50x, but Zoetis is a larger and more profitable company in terms of absolute revenue and earnings.

This premium valuation, however, is not without justification. Zoetis earns its higher multiple through its superior financial profile.

As highlighted previously, its growth rates, profitability margins, ROE, and ROIC are all best-in-class, placing it in an elite category of high-quality compounders. An A+ Investor Quality Grade analysis confirms this, giving Zoetis an ‘A’ for both Growth and Quality, far surpassing a peer like Sanofi, which scores ‘C’ and ‘B’ in those respective categories. The market is willing to pay a higher price for Zoetis’s superior and more predictable performance.

6.2. Discounted Cash Flow (DCF) Model: Unlocking Intrinsic Value

While relative valuation provides useful context, a DCF model offers a clearer view of a company’s intrinsic value based on its long-term cash-generating capacity. This is where the undervaluation thesis for Zoetis becomes most apparent.

Multiple independent DCF analyses, which project the company’s future free cash flows and discount them back to the present, arrive at a similar conclusion. The key inputs for these models are:

• Free Cash Flow (FCF): Zoetis generated a robust $2.3 billion in free cash flow in 2024, a remarkable 41% increase from the prior year. Analyst projections forecast this to grow to approximately $3.3 billion by 2029.
• Discount Rate: Reflecting the stock’s lower-than-market volatility (beta of ~0.9), a cost of equity between 6.2% and 6.8% is a reasonable assumption for the discount rate.
• Terminal Growth Rate: A conservative perpetual growth rate of around 3.1%, in line with long-term government bond yields, is used to model cash flows beyond the initial forecast period.

Based on these inputs, the DCF models consistently calculate an intrinsic value for Zoetis in the range of $178 to $192 per share. This suggests that, based on its fundamental ability to generate cash for its shareholders over the long term, the stock is currently trading at a substantial 18% to 23% discount to its true fair value.

6.3. Scenario Analysis & 1-6 Month Price Outlook

To assess the stock’s potential trajectory over the next one to six months, a scenario analysis can be applied based on the resolution of key uncertainties. Using the current price of ~$146 as a baseline:

• Base Case (Fair Value: ~$165): This scenario assumes the upcoming earnings reports meet consensus expectations. It anticipates a modest sequential improvement in Librela sales, demonstrating stabilization, but no major developments regarding the EU investigation. In this environment, the stock would likely recover from its oversold condition and gradually drift higher, closing some of the gap to its 200-day moving average. This valuation is derived by applying a slightly compressed forward P/E of 24x to the consensus 2025 EPS forecast of $6.35, yielding a price of ~$152, with an additional premium for improving market sentiment.
• Bull Case (Fair Value: ~$185): This optimistic scenario would be triggered by one of two major positive catalysts: a favorable resolution or update on the EU antitrust probe, or a significant re-acceleration in the OA pain franchise reported in the next earnings release. Either event would remove a major overhang and restore investor confidence in the long-term growth story. The stock would begin to re-rate higher, moving toward its DCF-derived intrinsic value as the primary risk factor dissipates.
• Bear Case (Fair Value: ~$135): This negative scenario would materialize if the company faces a negative development in the EU investigation (such as a formal Statement of Objections) and simultaneously reports another quarter of weak or declining sales from its OA pain products, forcing a downward revision to its full-year guidance. This would confirm the market’s worst fears about both regulatory risk and slowing growth, causing the stock to break below its 52-week low of $139 and its valuation multiple to compress further to ~21x forward earnings.

6.4. Deriving a 12-Month Price Target: $188

The 12-month price target of $188 is derived from a blended valuation approach that gives significant weight to the company’s long-term intrinsic value and forward-looking estimates.

1. DCF Valuation: The fundamental, cash-flow-based valuation points to a fair value of approximately $180 per share.
2. Analyst Consensus: The average 12-month price target from Wall Street analysts is approximately $192.
3. Forward P/E Multiple: Applying a 27x forward P/E multiple to the 2026 consensus EPS estimate of $6.87 yields a target of $185. The 27x multiple represents a modest expansion from the current ~25x, justified by an expected resolution of the near-term uncertainties over the next 12 months.

Averaging these three methodologies provides strong support for a price target in the high $180s. Therefore, a 12-month price target of $188 is established.

7. Conclusion: The Bull vs. Bear Case & Final Recommendation

7.1. The Bull Case (Why to Buy)

The investment case for Zoetis is rooted in its exceptional quality and the current dislocation between its stock price and its intrinsic value. Key bullish arguments include:

• Wide Economic Moat: Zoetis enjoys a dominant market position, unparalleled brand equity with veterinarians, a deep portfolio of patent-protected blockbuster products, and significant economies of scale.
• Durable Secular Growth: The company is perfectly positioned to benefit from the powerful, non-discretionary, long-term trends of pet humanization and the growing global demand for animal protein.
• Superior Financial Profile: Zoetis exhibits best-in-class profitability, with industry-leading margins, ROE, and ROIC. It is a highly predictable cash flow machine with a strong balance sheet.
• Compelling Valuation Opportunity: Due to temporary and, in our view, solvable issues, the stock is trading at a rare and significant discount to its DCF-derived fair value, offering an attractive entry point for long-term investors.

7.2. The Bear Case (Reasons for Caution)

Investors must also weigh the significant risks and reasons for caution before investing. The primary bearish arguments include:

• Premium Valuation: On a relative basis, the stock’s P/E ratio remains high compared to the broader market and many of its peers, making it vulnerable to further multiple compression if growth disappoints.
• Execution Risk: The slower-than-expected U.S. launch of the critical OA pain franchise raises legitimate questions about the company’s ability to meet lofty market expectations for its next wave of growth drivers.
• Regulatory Overhang: The EU antitrust investigation is a major, unresolved risk that could result in a substantial financial penalty and damage to the company’s reputation.
• Intensifying Competition: The lucrative markets that Zoetis pioneered, particularly in dermatology, are now attracting new competitors, which could threaten to erode market share and pricing power in the coming years.

7.3. Final Recommendation: BUY

After a thorough analysis of the company’s fundamentals, market position, and the risks it faces, this report initiates coverage on Zoetis Inc. with a BUY rating and a 12-month price target of $188.

The evidence strongly suggests that the market has overly penalized the stock for near-term challenges while undervaluing the company’s exceptional quality and durable long-term growth prospects. The current disconnect between the stock price and its fundamental value presents a compelling opportunity. It is recommended that long-term, growth-oriented investors use the current period of market pessimism to build a core position in this best-in-class industry leader.